Health TidingsGilead to Pay $1.275B for Oral IL-23R Inhibitor HCXT-2001 Gilead to Pay $1.275B for Oral IL-23R Inhibitor HCXT-2001 Read Post »
Health TidingsMerck, Moderna Show Improved Recurrence-Free Survival in Melanoma Trial Merck, Moderna Show Improved Recurrence-Free Survival in Melanoma Trial Read Post »
Clinical TrialsMineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Mineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Read Post »
Clinical TrialsVor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Vor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Read Post »
Clinical TrialsAbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa AbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa Read Post »
Health Tidings Mergers & AcquisitionsMenarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Menarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Read Post »
Clinical TrialsOtsuka Reports 97.1% Lower Kidney Outcome Risk With VOYXACT Otsuka Reports 97.1% Lower Kidney Outcome Risk With VOYXACT Read Post »
Health TidingsBoehringer, Microsoft Explore AI Twins for Clinical Trials Boehringer, Microsoft Explore AI Twins for Clinical Trials Read Post »
Health TidingsBioNTech to Test Pumitamig With Trodelvy in Advanced TNBC BioNTech to Test Pumitamig With Trodelvy in Advanced TNBC Read Post »
Health TidingsApollo’s APL-9796 Advances With Evidence of ZIP12-Driven Vascular Remodel... Apollo’s APL-9796 Advances With Evidence of ZIP12-Driven Vascular Remodel... Read Post »
Health TidingsAI Proteins, Astellas Strike $400M+ Deal for Miniprotein Drug Discovery AI Proteins, Astellas Strike $400M+ Deal for Miniprotein Drug Discovery Read Post »
Health TidingsHanchorBio, Aston Sci Pair HCB101 With AST-301 for Cancer Immunotherapy HanchorBio, Aston Sci Pair HCB101 With AST-301 for Cancer Immunotherapy Read Post »
Clinical TrialsTG Reports 7-Year BRIUMVI Outcomes and Positive ENHANCE Results TG Reports 7-Year BRIUMVI Outcomes and Positive ENHANCE Results Read Post »
Clinical TrialsShionogi Reports 76.7% Clinical Response With Cefiderocol in U.S. Cohort Shionogi Reports 76.7% Clinical Response With Cefiderocol in U.S. Cohort Read Post »
Clinical TrialsOculis Reports Reduced NfL and GFAP Rises in Phase 2 ACUITY Trial Oculis Reports Reduced NfL and GFAP Rises in Phase 2 ACUITY Trial Read Post »
Health TidingsCognition Therapeutics Aligns With FDA on Zervimesine Phase 3 Trial Cognition Therapeutics Aligns With FDA on Zervimesine Phase 3 Trial Read Post »
Health TidingsViiV Reports 77% Cabenuva Treatment Persistence in U.S. Cohort ViiV Reports 77% Cabenuva Treatment Persistence in U.S. Cohort Read Post »
Health TidingsNovartis Secures EU Approval for Cosentyx in PMR Novartis Secures EU Approval for Cosentyx in PMR Read Post »
Clinical TrialsSavara Reports Gas-Transfer Gains with Molgramostim in aPAP Savara Reports Gas-Transfer Gains with Molgramostim in aPAP Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca, Oracle Link Real-World Data With Clinical Research AstraZeneca, Oracle Link Real-World Data With Clinical Research Read Post »
New Drug ApprovalAstraZeneca Wins FDA Approval for Ultomiris in IgA Nephropathy AstraZeneca Wins FDA Approval for Ultomiris in IgA Nephropathy Read Post »
Clinical TrialsTaiMed Reports Up to 1.57-Log HIV-1 RNA Reduction With TMB-365 TaiMed Reports Up to 1.57-Log HIV-1 RNA Reduction With TMB-365 Read Post »
Health TidingsKyverna Reports 49% Walking Improvement With Miv-cel at One Year Kyverna Reports 49% Walking Improvement With Miv-cel at One Year Read Post »
New Drug ApprovalMerck Wins EU Approval for KEYTRUDA Plus Padcev in Resectable MIBC Merck Wins EU Approval for KEYTRUDA Plus Padcev in Resectable MIBC Read Post »
Clinical TrialsRoche Reports Reduced Chronic Lesion Activity Across MS Trials Roche Reports Reduced Chronic Lesion Activity Across MS Trials Read Post »
Clinical TrialsRoivant Reports Positive Phase 3 Results for Brepocitinib in Uveitis Roivant Reports Positive Phase 3 Results for Brepocitinib in Uveitis Read Post »
New Drug ApprovalBioCryst Wins FDA Approval for ORLADEYO 150 mg Pellets in HAE BioCryst Wins FDA Approval for ORLADEYO 150 mg Pellets in HAE Read Post »
Health TidingsShionogi, F2G Report Olorofim Non-Inferiority in Aspergillosis Shionogi, F2G Report Olorofim Non-Inferiority in Aspergillosis Read Post »
Health TidingsAltruBio Reports Early Remission and Endoscopic Improvement With ALTB-268 AltruBio Reports Early Remission and Endoscopic Improvement With ALTB-268 Read Post »
New Drug ApprovalGSK Gains FDA Approval for Hibsago After Positive B-WELL Trials GSK Gains FDA Approval for Hibsago After Positive B-WELL Trials Read Post »
New Drug ApprovalFDA Approves EVOXAC Oral Solution for Sjögren’s Disease FDA Approves EVOXAC Oral Solution for Sjögren’s Disease Read Post »
Health TidingsSummit Partners With ECOG-ACRIN to Advance Ivonescimab in Biliary Cancer Summit Partners With ECOG-ACRIN to Advance Ivonescimab in Biliary Cancer Read Post »
Clinical TrialsLumen’s LMN-201 Shows Positive RePreve Results in C. difficile Lumen’s LMN-201 Shows Positive RePreve Results in C. difficile Read Post »
Health TidingsNano24 Reports Positive EXO-CD24 Results in Phase 2b ARDS Trial Nano24 Reports Positive EXO-CD24 Results in Phase 2b ARDS Trial Read Post »
Clinical TrialsRapport’s RAP-219 Delivers Significant YMRS Improvement in Phase 2 Rapport’s RAP-219 Delivers Significant YMRS Improvement in Phase 2 Read Post »
GenericsZydus Gains FDA Approval for Weekly Menopause Hormone Therapy Zydus Gains FDA Approval for Weekly Menopause Hormone Therapy Read Post »
Health TidingsSun Pharma’s UNLOXCYT Gains Preferred NCCN Status for Advanced Skin Cance... Sun Pharma’s UNLOXCYT Gains Preferred NCCN Status for Advanced Skin Cance... Read Post »
Clinical TrialsAstraZeneca and Amgen Report Sustained Histologic Remission With Tezspire AstraZeneca and Amgen Report Sustained Histologic Remission With Tezspire Read Post »
Clinical TrialsTeva and Sanofi Report Sustained Week 44 Duvakitug Outcomes in IBD Teva and Sanofi Report Sustained Week 44 Duvakitug Outcomes in IBD Read Post »
Health TidingsMerck KGaA to Acquire Silence Therapeutics in $1.3B Deal Merck KGaA to Acquire Silence Therapeutics in $1.3B Deal Read Post »
Health TidingsGilead Reports Positive Results for Emvistegrast in Ulcerative Colitis Gilead Reports Positive Results for Emvistegrast in Ulcerative Colitis Read Post »
New Drug ApprovalJemperli Wins FDA Approval for MSI-H/dMMR Rectal Cancer Jemperli Wins FDA Approval for MSI-H/dMMR Rectal Cancer Read Post »
Clinical TrialsJ&J Reports Long-Term Crohn’s Outcomes and Fistula Data for TREMFYA J&J Reports Long-Term Crohn’s Outcomes and Fistula Data for TREMFYA Read Post »
Health Tidings Mergers & AcquisitionsHansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Hansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Read Post »
Clinical TrialsXBiotech’s Vilamakitug Meets TASKIN Trial’s 12-Month Survival Threshold XBiotech’s Vilamakitug Meets TASKIN Trial’s 12-Month Survival Threshold Read Post »
Health Tidingsargenx Efgartigimod Improves Autoimmune Myositis in Phase 3 argenx Efgartigimod Improves Autoimmune Myositis in Phase 3 Read Post »
Clinical TrialsVeradermics Reports Higher Hair Growth With VDPHL01 in Phase 3 Veradermics Reports Higher Hair Growth With VDPHL01 in Phase 3 Read Post »
Health TidingsOSE Reports Positive Tedopi Results in Metastatic NSCLC OSE Reports Positive Tedopi Results in Metastatic NSCLC Read Post »
Clinical TrialsDisc’s Bitopertin Meets All Phase 3 APOLLO Endpoints in EPP Disc’s Bitopertin Meets All Phase 3 APOLLO Endpoints in EPP Read Post »
Clinical TrialsEyePoint’s DURAVYU Fails Wet AMD Trial EyePoint’s DURAVYU Fails Wet AMD Trial Read Post »
